7results about How to "Improve mitochondrial function" patented technology

The invention belongs to the technical field of biology, and discloses siRNA for inhibiting BNIP3L protein expression and application of the siRNA in preparation of a medicine for resisting myocardial cell hypoxia injury. The siRNA for inhibiting BNIP3L protein expression is composed of a positive-sense strand and an antisense strand, the nucleotide sequence of the positive-sense strand is as shown in SEQ ID No. 1, and the nucleotide sequence of the antisense strand is as shown in SEQ ID No. 2. The siRNA for inhibiting the expression of the BNIP3L protein can obviously inhibit the expression of the BNIP3L of myocardial cells H9c2, down-regulate the autophagy level of mitochondria and obviously enhance the cell activity and mitochondrial function of the myocardial cells under hypoxia, and has the effect of resisting hypoxia-induced myocardial injury.

The application belongs to the technical field of biological nanomaterials, and particularly relates to a nano-enzyme material and a preparation method and application thereof. The application reacts dimethyl imidazole and metal salt in an aqueous solution to obtain a metal-dimethyl imidazole composite material solution, wherein the metal salt comprises copper salt and / or zinc salt; and reacts the metal-dimethyl imidazole composite material solution and tannic acid to obtain a nano-enzyme material. The nano-enzyme material provided by the application has excellent antioxidant enzyme-like catalytic activity and good biocompatibility, can effectively remove abnormally increased reactive oxygen species (ROS) in the process of myocardial infarction and myocardial ischemia-reperfusion injury, inhibit inflammatory response and myocardial cell apoptosis, improve the mitochondrial function state, thereby promoting the repair of damaged myocardial tissue and significantly improving the cardiac function, and provides a new technical solution for the treatment of myocardial infarction and related ischemic cardiovascular diseases.

The invention discloses a spermidine composition for inhibiting aging of hair follicle stem cells and promoting growth period entry and application, and relates to the technical field of biological medicine and functional skin care. The invention discloses a spermidine composition for inhibiting aging of hair follicle stem cells and promoting growth period entry. The skin care product is prepared from the following components in parts by mass: 0.5 to 3 parts of spermidine, 0.2 to 2 parts of an autophagy activator, 0.5 to 4 parts of an antioxidant, 0.1 to 2 parts of a mitochondrial function accelerant, 0.2 to 3 parts of a microcirculation accelerant, 1 to 6 parts of a skin penetration accelerant, 0.2 to 1 part of a preservative, 0.05 to 0.4 part of a pH regulator and 60 to 95 parts of a carrier matrix. The composition can effectively reduce the aging rate of hair follicle stem cells and remarkably improve the proliferation activity of the hair follicle stem cells, active oxygen free radicals around the hair follicle stem cells can be effectively removed by adding the antioxidant of a novel structure, damage of external stimulation to hair follicles is reduced, and a systematic cell protection and repair mechanism is formed.

The invention relates to application of microorganism-derived outer membrane vesicles in medicines for treating obesity and related metabolic diseases, and belongs to the technical field of exosomes. In order to solve the technical problems that probiotics beneficial to intestinal tracts are weak in colonization ability in the intestinal tracts, are easily influenced by gastrointestinal tract environments and are unstable in individual response, the sphingosine-containing microbe-sourced outer membrane vesicle is provided, and the sphingosine content in the outer membrane vesicle is 50-65 ng / mg.

The invention discloses an application of a cell endogenous metabolite in preparation of a medicine for treating and / or preventing senescence. The cell endogenous metabolite is any one or a combination of more of phosphocreatine, hypotaurine and / or ethanolamine phosphate. The invention finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively recover cell growth, reduce SA-beta-Gal staining intensity of cells, improve mitochondrial functions of the cells, increase ATP yield, recover mitochondrial membrane potential of the cells and relieve damage and premature aging caused by oxidative stress of the cells under a specific concentration. The life of the nematodes can be prolonged; the exercise ability in the aging middle stage is recovered. Meanwhile, the three metabolites have a synergistic effect, and the same cell protection effect can be achieved by adjusting the proportioning concentration of the three metabolites and performing mixed administration. The endogenous metabolites have the characteristics of accuracy, high efficiency and safety at the same time, so that the three cell endogenous metabolites provided by the invention can be used for preparing anti-aging drugs.

The invention discloses a composition acting on an ovary somatic cell membrane structure and application of the composition. The composition acting on the ovary somatic cell membrane structure comprises the following components in parts by weight: 12-18 parts of a clove extract, 4-8 parts of a sophora flower bud extract, 8-12 parts of Chinese yam protein polypeptide, 4-8 parts of a cranberry extract and 8-12 parts of a citrus extract. The composition can act on an ovary somatic cell membrane structure to improve the mitochondrial function of oocytes, increase the number of the oocytes and reduce the fragment rate of the oocytes, so that the ovary function of elderly women is improved, and the purposes of improving the fertility and delaying senescence are achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of limonin in preparation of a medicine for improving renal fibrosis. The limonin used in the invention is also named evodia lactone, the CAS number of the limonin is 1180-71-8, the molecular formula of the limonin is C26H30O8, and the structure of the limonin compound is as shown in the formula I. The limonin compound can be applied to the field of pharmaceutical chemistry. According to the application, a unilateral ureteral obstruction model is constructed, a positive drug captopril is taken as a control group, and the application of limonin in improvement of renal fibrosis caused by acute kidney injury is verified. Results of embodiments show that limonin not only has low cytotoxicity and high safety, but also has anti-inflammatory and anti-fibrosis effects, and can inhibit proliferation and migration of renal fibroblasts and improve mitochondrial functions of renal epithelial cells.